Ajiro, M., Jia, R., Yang, Y., Zhu, J., and Zheng, Z.-M. (2016). A genome land- scape of SRSF3-regulated splicing events and gene expression in human os- teosarcoma U2OS cells. Nucleic Acids Res. 44, 1854–1870.
Alton, E.W.F.W., Armstrong, D.K., Ashby, D., Bayfield, K.J., Bilton, D., Bloomfield, E.V., Boyd, A.C., Brand, J., Buchan, R., Calcedo, R., et al. (2015). Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet. Respir. Med. 3, 684–691.
Awatade, N.T., Wong, S.L., Hewson, C.K., Fawcett, L.K., Kicic, A., Jaffe, A., and Waters, S.A. (2018). Human primary epithelial cell models: promising tools in the era of cystic fibrosis personalized medicine. Front. Pharmacol. 9, 1429.
Boisson, B., Honda, Y., Ajiro, M., Bustamante, J., Bendavid, M., Gennery, A.R., Kawasaki, Y., Ichishima, J., Osawa, M., Nihira, H., et al. (2019). Rescue of recurrent deep intronic mutation underlying cell type–dependent quantita- tive NEMO deficiency. J. Clin. Invest. 129, 583–597.
Buratti, E., Do¨ rk, T., Zuccato, E., Pagani, F., Romano, M., and Baralle, F.E. (2001). Nuclear factor TDP-43 and SR proteins promote in vitro and in vivo CFTR exon 9 skipping. EMBO J. 20, 1774–1784.
Buratti, E., Stuani, C., De Prato, G., and Baralle, F.E. (2007). SR protein-medi- ated inhibition of CFTR exon 9 inclusion: molecular characterization of the in- tronic splicing silencer. Nucleic Acids Res. 35, 4359–4368.
Cartegni, L., Chew, S.L., and Krainer, A.R. (2002). Listening to silence and un- derstanding nonsense: exonic mutations that affect splicing. Nat. Rev. Genet. 3, 285–298.
Chiba-Falek, O., Kerem, E., Shoshani, T., Aviram, M., Augarten, A., Bentur, L., Tal, A., Tullis, E., Rahat, A., and Kerem, B. (1998). The molecular basis of dis- ease variability among cystic fibrosis patients carrying the 3849+10 kb C/T mutation. Genomics 53, 276–283.
Cutting, G.R. (2015). Cystic fibrosis genetics: from molecular understanding to clinical application. Nat. Rev. Genet. 16, 45–56.
Davies, J.C., Moskowitz, S.M., Brown, C., Horsley, A., Mall, M.A., McKone, E.F., Plant, B.J., Prais, D., Ramsey, B.W., Taylor-Cousar, J.L., et al. (2018). VX-659-tezacaftor-ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles. N. Engl. J. Med. 379, 1599–1611.
Dufner-Almeida, L.G., do Carmo, R.T., Masotti, C., and Haddad, L.A. (2019). Understanding human DNA variants affecting pre-mRNA splicing in the NGS era. Adv. Genet. 103, 39–90.
Elborn, J.S. (2016). Cystic fibrosis. Lancet 388, 2519–2531.
Fajac, I., and Wainwright, C.E. (2017). New treatments targeting the basic de- fects in cystic fibrosis. Press. Med. 46, e165–e175.
Fedorov, O., Huber, K., Eisenreich, A., Filippakopoulos, P., King, O., Bullock, A.N., Szklarczyk, D., Jensen, L.J., Fabbro, D., Trappe, J., et al. (2011). Specific CLK inhibitors from a novel chemotype for regulation of alternative splicing. Chem. Biol. 18, 67–76.
Finkel, R.S., Mercuri, E., Darras, B.T., Connolly, A.M., Kuntz, N.L., Kirschner, J., Chiriboga, C.A., Saito, K., Servais, L., Tizzano, E., et al. (2017). Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N. Engl. J. Med. 377, 1723–1732.
Fowler, D.K., Stewart, S., Seredick, S., Eisen, J.S., Stankunas, K., and Washbourne, P. (2016). A multisite gateway toolkit for rapid cloning of verte- brate expression constructs with diverse research applications. PLoS One 11, e0159277.
Friedman, K.J., Kole, J., Cohn, J.A., Knowles, M.R., Silverman, L.M., and Kole, R. (1999). Correction of aberrant splicing of the cystic fibrosis transmembrane conductance regulator (CFTR) gene by antisense oligonucleotides. J. Biol. Chem. 274, 36193–36199.
Fu, X.-D., and Ares, M. (2014). Context-dependent control of alternative splicing by RNA-binding proteins. Nat. Rev. Genet. 15, 689–701.
Fukuhara, T., Hosoya, T., Shimizu, S., Sumi, K., Oshiro, T., Yoshinaka, Y., Suzuki, M., Yamamoto, N., Herzenberg, L.A., Herzenberg, L.A., et al. (2006). Utilization of host SR protein kinases and RNA-splicing machinery during viral replication. Proc. Natl. Acad. Sci. U S A 103, 11329–11333.
Funnell, T., Tasaki, S., Oloumi, A., Araki, S., Kong, E., Yap, D., Nakayama, Y., Hughes, C.S., Cheng, S.-W.G., Tozaki, H., et al. (2017). CLK-dependent exon recognition and conjoined gene formation revealed with a novel small mole- cule inhibitor. Nat. Commun. 8, 7.
Galietta, L.J., Haggie, P.M., and Verkman, A.S. (2001). Green fluorescent pro- tein-based halide indicators with improved chloride and iodide affinities. FEBS Lett. 499, 220–224.
Gao, K., Masuda, A., Matsuura, T., and Ohno, K. (2008). Human branch point consensus sequence is yUnAy. Nucleic Acids Res. 36, 2257–2267.
Ghosh, G., and Adams, J.A. (2011). Phosphorylation mechanism and structure of serine-arginine protein kinases. FEBS J. 278, 587–597.
Gonorazky, H., Liang, M., Cummings, B., Lek, M., Micallef, J., Hawkins, C., Basran, R., Cohn, R., Wilson, M.D., MacArthur, D., et al. (2016). RNAseq anal- ysis for the diagnosis of muscular dystrophy. Ann. Clin. Transl. Neurol. 3, 55–60.
Van Goor, F., Hadida, S., Grootenhuis, P.D.J., Burton, B., Stack, J.H., Straley, K.S., Decker, C.J., Miller, M., McCartney, J., Olson, E.R., et al. (2011). Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc. Natl. Acad. Sci. U S A 108, 18843–18848.
Haque, A., Buratti, E., and Baralle, F.E. (2010). Functional properties and evolutionary splicing constraints on a composite exonic regulatory element of splicing in CFTR exon 12. Nucleic Acids Res. 38, 647–659.
Highsmith, W.E., Burch, L.H., Zhou, Z., Olsen, J.C., Boat, T.E., Spock, A., Gorvoy, J.D., Quittell, L., Friedman, K.J., Silverman, L.M., et al. (1994). A novel mutation in the cystic fibrosis gene in patients with pulmonary disease but normal sweat chloride concentrations. N. Engl. J. Med. 331, 974–980.
Hua, Y., Vickers, T.A., Okunola, H.L., Bennett, C.F., and Krainer, A.R. (2008). Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice. Am. J. Hum. Genet. 82, 834–848.
Iwai, K., Yaguchi, M., Nishimura, K., Yamamoto, Y., Tamura, T., Nakata, D., Dairiki, R., Kawakita, Y., Mizojiri, R., Ito, Y., et al. (2018). Anti-tumor efficacy of a novel CLK inhibitor via targeting RNA splicing and MYC-dependent vulner- ability. EMBO Mol. Med. 10, e8289.
Kallen, J., Bergsdorf, C., Arnaud, B., Bernhard, M., Brichet, M., Cobos-Correa, A., Elhajouji, A., Freuler, F., Galimberti, I., Guibourdenche, C., et al. (2018). X- ray structures and feasibility assessment of CLK2 inhibitors for phelan- McDermid syndrome. ChemMedChem 13, 1997–2007.
Keating, D., Marigowda, G., Burr, L., Daines, C., Mall, M.A., McKone, E.F., Ramsey, B.W., Rowe, S.M., Sass, L.A., Tullis, E., et al. (2018). VX-445-tezacaf- tor-ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles. N. Engl. J. Med. 379, 1612–1620.
Khan, A.O., Becirovic, E., Betz, C., Neuhaus, C., Altmuller, J., Maria Riedmayr, L., Motameny, S., Nurnberg, G., Nurnberg, P., and Bolz, H.J. (2017). A deep intronic CLRN1 (USH3A) founder mutation generates an aberrant exon and un- derlies severe Usher syndrome on the Arabian Peninsula. Sci. Rep. 7, 1411.
Kuroyanagi, H., Ohno, G., Sakane, H., Maruoka, H., and Hagiwara, M. (2010). Visualization and genetic analysis of alternative splicing regulation in vivo using fluorescence reporters in transgenic Caenorhabditis elegans. Nat. Protoc. 5, 1495–1517.
Lee, M., Roos, P., Sharma, N., Atalar, M., Evans, T.A., Pellicore, M.J., Davis, E., Lam, A.-T.N., Stanley, S.E., Khalil, S.E., et al. (2017). Systematic computa- tional identification of variants that activate exonic and intronic cryptic splice sites. Am. J. Hum. Genet. 100, 751–765.
Maule, G., Casini, A., Montagna, C., Ramalho, A.S., De Boeck, K., Debyser, Z., Carlon, M.S., Petris, G., and Cereseto, A. (2019). Allele specific repair of splicing mutations in cystic fibrosis through AsCas12a genome editing. Nat. Commun. 10, 3556.
Mercuri, E., Darras, B.T., Chiriboga, C.A., Day, J.W., Campbell, C., Connolly, A.M., Iannaccone, S.T., Kirschner, J., Kuntz, N.L., Saito, K., et al. (2018). Nusinersen versus sham control in later-onset spinal muscular atrophy. N. Engl. J. Med. 378, 625–635.
Merkert, S., Schubert, M., Olmer, R., Engels, L., Radetzki, S., Veltman, M., Scholte, B.J., Zollner, J., Pedemonte, N., Galietta, L.J.V., et al. (2019). High- throughput screening for modulators of CFTR activity based on genetically en- gineered cystic fibrosis disease-specific iPSCs. Stem Cell Rep. 12, 1389–1403.
Molinski, S.V., Ahmadi, S., Ip, W., Ouyang, H., Villella, A., Miller, J.P., Lee, P.-S., Kulleperuma, K., Du, K., Di Paola, M., et al. (2017). Orkambi® and ampli- fier co-therapy improves function from a rare CFTR mutation in gene-edited cells and patient tissue. EMBO Mol. Med. 9, 1224–1243.
Moss, R.B., Milla, C., Colombo, J., Accurso, F., Zeitlin, P.L., Clancy, J.P., Spencer, L.T., Pilewski, J., Waltz, D.A., Dorkin, H.L., et al. (2007). Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized pla- cebo-controlled phase 2B trial. Hum. Gene Ther. 18, 726–732.
Muraki, M., Ohkawara, B., Hosoya, T., Onogi, H., Koizumi, J., Koizumi, T., Sumi, K., Yomoda, J.I., Murray, M.V., Kimura, H., et al. (2004). Manipulation of alternative splicing by a newly developed inhibitor of Clks. J. Biol. Chem. 279, 24246–24254.
Nishida, A., Kataoka, N., Takeshima, Y., Yagi, M., Awano, H., Ota, M., Itoh, K., Hagiwara, M., and Matsuo, M. (2011). Chemical treatment enhances skipping of a mutated exon in the dystrophin gene. Nat. Commun. 2, 308.
Pagani, F., Stuani, C., Tzetis, M., Kanavakis, E., Efthymiadou, A., Doudounakis, S., Casals, T., and Baralle, F.E. (2003). New type of disease causing mutations: the example of the composite exonic regulatory elements of splicing in CFTR exon 12. Hum. Mol. Genet. 12, 1111–1120.
Papatheodorou, I., Fonseca, N.A., Keays, M., Tang, Y.A., Barrera, E., Bazant, W., Burke, M., Fu€llgrabe, A., Fuentes, A.M.P., George, N., et al. (2018). Expression Atlas: gene and protein expression across multiple studies and or- ganisms. Nucleic Acids Res. 46, D246–D251.
Ramsey, B.W., Davies, J., McElvaney, N.G., Tullis, E., Bell, S.C., Dˇrevı´nek, P., Griese, M., McKone, E.F., Wainwright, C.E., Konstan, M.W., et al. (2011). A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N. Engl. J. Med. 365, 1663–1672.
Riant, F., Odent, S., Cecillon, M., Pasquier, L., de Barace, C., Carney, M.P., and Tournier-Lasserve, E. (2014). Deep intronic KRIT1 mutation in a family with clinically silent multiple cerebral cavernous malformations. Clin. Genet. 86, 585–588.
Rowe, S.M., Miller, S., and Sorscher, E.J. (2005). Cystic fibrosis. N. Engl. J. Med. 352, 1992–2001.
Rowe, S.M., Daines, C., Ringshausen, F.C., Kerem, E., Wilson, J., Tullis, E., Nair, N., Simard, C., Han, L., Ingenito, E.P., et al. (2017). Tezacaftor-ivacaftor in residual-function heterozygotes with cystic fibrosis. N. Engl. J. Med. 377, 2024–2035.
Sakuma, M., Iida, K., and Hagiwara, M. (2015). Deciphering targeting rules of splicing modulator compounds: case of TG003. BMC Mol. Biol. 16, 16.
Sharma, N., Sosnay, P.R., Ramalho, A.S., Douville, C., Franca, A., Gottschalk, L.B., Park, J., Lee, M., Vecchio-Pagan, B., Raraigh, K.S., et al. (2014). Experimental assessment of splicing variants using expression minigenes and comparison with in silico predictions. Hum. Mutat. 35, 1249–1259.
Sharma, N., Evans, T.A., Pellicore, M.J., Davis, E., Aksit, M.A., McCague, A.F., Joynt, A.T., Lu, Z., Han, S.T., Anzmann, A.F., et al. (2018). Capitalizing on the heterogeneous effects of CFTR nonsense and frameshift variants to inform therapeutic strategy for cystic fibrosis. PLoS Genet. 14, e1007723.
Sibley, C.R., Blazquez, L., and Ule, J. (2016). Lessons from non-canonical splicing. Nat. Rev. Genet. 17, 407–421.
Sonamoto, R., Kii, I., Koike, Y., Sumida, Y., Kato-Sumida, T., Okuno, Y., Hosoya, T., and Hagiwara, M. (2015). Identification of a DYRK1A inhibitor that induces degradation of the target kinase using co-chaperone CDC37 fused with luciferase nanoKAZ. Sci. Rep. 5, 12728.
Sondhi, D., Stiles, K.M., De, B.P., and Crystal, R.G. (2017). Genetic modifica- tion of the lung directed toward treatment of human disease. Hum. Gene Ther. 28, 3–84.
Vaz-Drago, R., Custodio, N., and Carmo-Fonseca, M. (2017). Deep intronic mutations and human disease. Hum. Genet. 136, 1093–1111.
Virant-Young, D., Thomas, J., Woiderski, S., Powers, M., Carlier, J., McCarty, J., Kupchick, T., and Larder, A. (2015). Cystic fibrosis: a novel pharmacologic approach to cystic fibrosis transmembrane regulator modulation therapy. J. Am. Osteopath. Assoc. 115, 546–555.
Yoshida, M., Kataoka, N., Miyauchi, K., Ohe, K., Iida, K., Yoshida, S., Nojima, T., Okuno, Y., Onogi, H., Usui, T., et al. (2015). Rectifier of aberrant mRNA splicing recovers tRNA modification in familial dysautonomia. Proc. Natl. Acad. Sci. U S A 112, 2764–2769.
論文の公開元へ
